- Home
- NBIX vs ZTO Comparison
NBIX vs ZTO Comparison
Compare NBIX & ZTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- ZTO
- Stock Information
- Founded
- NBIX 1992
- ZTO 2002
- Country
- NBIX United States
- ZTO China
- Employees
- NBIX N/A
- ZTO N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- ZTO Advertising
- Sector
- NBIX Health Care
- ZTO Consumer Discretionary
- Exchange
- NBIX Nasdaq
- ZTO Nasdaq
- Market Cap
- NBIX 12.2B
- ZTO 13.4B
- IPO Year
- NBIX 1996
- ZTO 2016
- Fundamental
- Price
- NBIX $126.55
- ZTO $17.21
- Analyst Decision
- NBIX Strong Buy
- ZTO Buy
- Analyst Count
- NBIX 20
- ZTO 5
- Target Price
- NBIX $163.20
- ZTO $22.64
- AVG Volume (30 Days)
- NBIX 915.2K
- ZTO 2.5M
- Earning Date
- NBIX 07-31-2025
- ZTO 08-19-2025
- Dividend Yield
- NBIX N/A
- ZTO 4.07%
- EPS Growth
- NBIX N/A
- ZTO N/A
- EPS
- NBIX 2.96
- ZTO 1.22
- Revenue
- NBIX $2,412,600,000.00
- ZTO $6,230,576,589.00
- Revenue This Year
- NBIX $16.29
- ZTO $16.57
- Revenue Next Year
- NBIX $15.08
- ZTO $12.82
- P/E Ratio
- NBIX $42.49
- ZTO $13.97
- Revenue Growth
- NBIX 21.73
- ZTO 14.76
- 52 Week Low
- NBIX $84.23
- ZTO $16.34
- 52 Week High
- NBIX $157.98
- ZTO $27.50
- Technical
- Relative Strength Index (RSI)
- NBIX 64.01
- ZTO 44.09
- Support Level
- NBIX $122.66
- ZTO $17.03
- Resistance Level
- NBIX $126.00
- ZTO $17.92
- Average True Range (ATR)
- NBIX 2.55
- ZTO 0.24
- MACD
- NBIX -0.33
- ZTO 0.03
- Stochastic Oscillator
- NBIX 72.06
- ZTO 26.21
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About ZTO ZTO Express (Cayman) Inc. each representing one ordinary share.
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 22.1% in 2022. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 77% voting rights as of June 30, 2023. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 11.7% interest.